Bristol-Myers Squibb Co`s
The failure of an Incyte immunotherapy drug in combination with Merck & Co`s
Gilead has a hefty $85 billion market capitalisation, making it only a target for the largest global drugmakers. Its product portfolio targets HIV/AIDS, hepatitis C, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. The company recently named a new CEO, Daniel O`Day, who previously headed Roche Holdings AG`s
Rare disease specialist Alexion, which has faced pressure from activist hedge fund Elliott Management could be an acquisition target for companies such as Amgen Inc
Raymond James analysts said in a research note that M&A could happen this year involving companies focussed on the huge unmet need for treating the progressive fatty liver disease known as NASH (non-alcoholic steatohepatitis), which does not yet have any approved treatments. Even though their shares did not get a boost on Thursday, Madrigal Pharmaceuticals
(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)
04:30 AM IST